1. Home
  2. DFLI vs CING Comparison

DFLI vs CING Comparison

Compare DFLI & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dragonfly Energy Holdings Corp. (NV)

DFLI

Dragonfly Energy Holdings Corp. (NV)

HOLD

Current Price

$2.08

Market Cap

49.0M

Sector

Technology

ML Signal

HOLD

CING

Cingulate Inc.

HOLD

Current Price

$4.05

Market Cap

59.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFLI
CING
Founded
2020
2012
Country
United States
United States
Employees
N/A
14
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.0M
59.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DFLI
CING
Price
$2.08
$4.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$3.25
$34.50
AVG Volume (30 Days)
448.3K
470.4K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$51.17
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.15
$3.20
52 Week High
$5.15
$11.89

Technical Indicators

Market Signals
Indicator
DFLI
CING
Relative Strength Index (RSI) 53.59 39.11
Support Level $1.89 $3.50
Resistance Level $2.26 $4.16
Average True Range (ATR) 0.14 0.49
MACD 0.03 -0.01
Stochastic Oscillator 74.79 16.61

Price Performance

Historical Comparison
DFLI
CING

About DFLI Dragonfly Energy Holdings Corp. (NV)

Dragonfly Energy Holdings Corp is a manufacturer of non-toxic deep cycle lithium-ion batteries that are designed to displace lead acid batteries in a number of different storage applications and end markets including RV, marine vessel, and solar and off-grid industries, with disruptive solid-state cell technology currently under development. The company's deep cycle lithium iron phosphate ("LFP") batteries provide numerous advantages compared to incumbent products, such as lead-acid batteries. LFP batteries are non-toxic and environmentally friendly, do not rely on scarce or controversial metals, and are a cost-effective storage solution.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: